Variables | Number (n) | Percentage (%) |
---|---|---|
All profile groups involved in the collaboration (n = 20) | ||
Biomedical researchers and health care professionals | 4 | 20 |
Biomedical researchers, health care professionals and clinical researchers | 8 | 40 |
Biomedical researchers, health care professionals, clinical researchers and specialists | 3 | 15 |
Biomedical researchers, health care professionals, specialists, clinical researchers and patients, citizens or users* | 3 | 15 |
Biomedical researchers, health care professionals, clinical researchers and patients, citizens or users* | 2 | 10 |
Field of study of biomedical researchers (n = 20) | ||
Biomedicine | 2 | 10 |
Neurosciences | 2 | 10 |
Cell biology | 1 | 5 |
Lipidology | 1 | 5 |
Molecular biology | 1 | 5 |
Neurointerventional research | 1 | 5 |
Mixed** | 6 | 30 |
Biomedicine | 3 | 50 |
Biotechnology | 2 | 33 |
Stem cell therapy | 2 | 33 |
Analytical chemistry | 1 | 17 |
Bioinformatics | 1 | 17 |
Biomaterials | 1 | 17 |
Cellomics | 1 | 17 |
Cell biology | 1 | 17 |
Cell Technology | 1 | 17 |
Chemistry | 1 | 17 |
Developmental biology and birth defects | 1 | 17 |
Energy | 1 | 17 |
Environmental biological technology | 1 | 17 |
Gene targeting | 1 | 17 |
Genomics | 1 | 17 |
Laparoscope technology | 1 | 17 |
Materials science | 1 | 17 |
Microscopy | 1 | 17 |
Molecular biology | 1 | 17 |
Pluripotent cell technology | 1 | 17 |
Proteomics | 1 | 17 |
Transgenesis | 1 | 17 |
Viral vectors | 1 | 17 |
Missing | 6 | 30 |
Types of health care professional (except specialists, n=20)** | ||
Physicians | 13 | 65 |
Nurses | 4 | 20 |
Pharmacists | 1 | 5 |
Dietitians | 1 | 5 |
Laboratory technicians | 1 | 5 |
Public health practitioners | 1 | 5 |
Presence of clinical researchers (n = 20) | ||
Yes | 15 | 75 |
No | 4 | 20 |
Missing | 1 | 5 |
Type of clinical researchers (n = 15) | ||
Clinician-researchers | 3 | 20 |
Clinician and non-clinician-researchers | 1 | 7 |
Missing | 11 | 73 |
Presence of specialists (n = 20) | ||
Yes | 7 | 35 |
No | 3 | 15 |
Missing | 10 | 50 |
Field of expertise of the specialists (n = 7) | ||
Mixed** | 6 | 86 |
Cardiology | 3 | 50 |
Epidemiology | 2 | 33 |
Pharmacology | 2 | 33 |
Atherothrombosis and Imaging | 1 | 17 |
Genetic medicine | 1 | 17 |
Internal medicine | 1 | 17 |
Nephrology | 1 | 17 |
Cardiovascular development and repair | 1 | 17 |
Community health | 1 | 17 |
Family and community medicine | 1 | 17 |
General medicine | 1 | 17 |
Geriatric | 1 | 17 |
Methodology in clinical research | 1 | 17 |
Neurology | 1 | 17 |
Psychiatry | 1 | 17 |
Public health | 1 | 17 |
Vascular biology and inflammation | 1 | 17 |
Vascular medicine | 1 | 17 |
Missing | 1 | 14 |
Presence of patients, citizens or users (n = 20) | ||
Yes | 7 | 35 |
“Patients” | 2 | 29 |
“Patients and citizens” | 2 | 29 |
“Patients and users” | 1 | 13 |
“Patients, citizens and users” | 2 | 29 |
No | 13 | 65 |
Roles of patients (n = 7) | ||
Patient participants**** | 4 | 70 |
Patient partners | 3 | 30 |
Roles of citizens or users (n = 6) | ||
Caregivers | 1 | 17 |
General public | 1 | 17 |
Policy and decision-makers | 1 | 17 |
Mixed** | 3 | 49 |
Academia | 1 | 33 |
Charities | 1 | 33 |
Clients and/or their representatives | 1 | 33 |
Caregivers | 1 | 33 |
Funding agency | 1 | 33 |
Health care directors | 1 | 33 |
National Health System | 1 | 33 |
Patient organizations | 1 | 33 |
Pharmaceutical company representatives | 1 | 33 |
Policy and decision-makers | 1 | 33 |
Regulatory science experts | 1 | 33 |
Scientific societies | 1 | 33 |
Stakeholders | 1 | 33 |
Teachers | 1 | 33 |